{"url":"https://whatshealthyandwhy.com/st-johns-wort/depression-and-mood","path":"/st-johns-wort/depression-and-mood","alternates":{"json":"https://whatshealthyandwhy.com/api/articles/st-johns-wort/depression-and-mood.json","markdown":"https://whatshealthyandwhy.com/st-johns-wort/depression-and-mood.md"},"topic":{"slug":"st-johns-wort","name":"St. John's Wort","url":"https://whatshealthyandwhy.com/st-johns-wort"},"slug":"depression-and-mood","order":1,"title":"Depression, Mood, and the Evidence","question":"Does St John's wort work for depression?","answer":"St John's wort probably helps mild to moderate depression about as well as standard antidepressants, but it is not supported for severe depression.","description":"Hypericum perforatum as a natural antidepressant — what clinical trials show, how it compares to SSRIs, and the drug interactions you need to know","confidence":4,"confidenceNote":"A meta-analysis of 37 RCTs favored it over placebo and matched antidepressants, but a 340-person JAMA trial in moderately severe depression was negative.","evidenceSummary":{"rctCount":2,"metaAnalysisCount":1,"totalParticipants":"2,000+","replicated":true,"newestStudyYear":2005},"category":{"categoryTitle":"What's Good For You","categorySlug":"good-for-you","subcategoryName":"Herbs & Spices","subcategorySlug":"herbs","url":"https://whatshealthyandwhy.com/explore/good-for-you/herbs"},"actions":["Choose an extract standardized to 3–5% hyperforin and 0.3% hypericin; low-hyperforin extracts worked less well in trials [1].","Standard trial dosing is 300 mg three times daily; allow 4–6 weeks before judging whether it works.","Before starting, ask a pharmacist or doctor to check all your medicines for interactions [4]."],"cautions":["Do not combine with SSRIs, SNRIs, tramadol or other serotonergic drugs: risk of serotonin syndrome.","It can weaken birth control pills, HIV drugs, immunosuppressants, warfarin, digoxin and some chemotherapy, causing documented treatment failures [4].","Not supported for severe depression, where a 340-person trial found no benefit over placebo; seek medical care for severe symptoms [3]."],"simpleText":"St. John's Wort (Hypericum perforatum) is one of the most extensively studied herbal medicines in the world. Dozens of randomized trials have tested it for mild to moderate depression, and a meta-analysis of 37 trials found it works better than placebo and comparably to standard antidepressants — with fewer side effects [1]. It's particularly meaningful for people who want to avoid pharmaceutical antidepressants or who experience intolerable side effects from them. The main caution: it interacts with a surprisingly large number of medications [4].","mediumText":"How St. John's Wort Works\n\nFor decades it was assumed that hypericin — the reddish pigment that gives the plant its name — was the active antidepressant compound. Research over the last 25 years has shifted this understanding to hyperforin, another constituent found in the resinous glands of the flowers and leaves.\n\nHyperforin inhibits the reuptake of serotonin, dopamine, norepinephrine, GABA, and L-glutamate simultaneously [2]. This is mechanistically different from SSRIs, which selectively block the serotonin transporter. Hyperforin achieves reuptake inhibition not by blocking transporters directly, but by elevating free intracellular sodium concentration — a novel mechanism that explains why the herb has a broader spectrum of action than most pharmaceutical antidepressants.\n\nThe clinical significance of hyperforin content is now well-established. Extracts standardized to 3-5% hyperforin consistently outperform those with low or no hyperforin in clinical trials. This makes extract quality critical: cheap, unstandardized products may have little active compound.\n\nWhat the Trials Show\n\nThe most comprehensive analysis of the evidence — a 2005 meta-analysis of 37 double-blind randomized trials — found that St. John's Wort monopreparations were significantly superior to placebo (relative risk 1.28-1.87) and statistically equivalent to standard antidepressants (relative risk 1.00-1.02) across trials targeting mild to moderate depression [1]. Side effects were consistently lower than for both tricyclic antidepressants and SSRIs.\n\nA major U.S. trial published in JAMA in 2002 tested St. John's Wort against sertraline (Zoloft) and placebo in 340 adults with moderately severe major depression [3]. Neither St. John's Wort nor sertraline outperformed placebo on the primary outcome — a reminder that even pharmacological antidepressants often struggle against placebo in severe depression, and that the herb may have limited efficacy outside the mild-to-moderate range.\n\nThe practical takeaway: St. John's Wort appears most effective for mild to moderate depression, which is where most people first look for help. It is not well-supported for severe depression or depression with psychotic features.\n\nDosage and Extract Quality\n\nStandard clinical dosing is 300 mg three times daily (900 mg total) of an extract standardized to 0.3% hypericin and 3-5% hyperforin. Most of the positive trials used WS 5570 (Perika) or ZE 117 (Remotiv) extracts, both of which are standardized products with consistent hyperforin content.\n\nOnset is typically 4 to 6 weeks — similar to pharmaceutical antidepressants. Don't judge effectiveness before 6 weeks of consistent use.\n\nDrug Interactions: The Critical Warning\n\nSt. John's Wort is a potent inducer of CYP3A4, a liver enzyme responsible for metabolizing roughly half of all pharmaceutical drugs [4]. A 14-day course of standard-dose St. John's Wort significantly increases CYP3A4 activity, reducing blood levels of drugs that depend on this pathway.\n\nMedications with clinically significant interactions include:\n- Oral contraceptives — reduced effectiveness; unintended pregnancies have been reported\n- HIV antiretrovirals (particularly protease inhibitors and NNRTIs)\n- Immunosuppressants (cyclosporine, tacrolimus) — organ rejection risk in transplant patients\n- Warfarin and anticoagulants\n- Digoxin\n- Some chemotherapy agents\n\nSt. John's Wort also carries a risk of serotonin syndrome if combined with SSRIs, SNRIs, tramadol, or other serotonergic drugs. This combination should be avoided entirely.\n\nAnyone taking prescription medications should consult a pharmacist or physician before using St. John's Wort.\n\nLight Sensitivity\n\nHypericin can cause photosensitivity — increased sensitivity of the skin to ultraviolet light — particularly at high doses. Fair-skinned individuals and those with significant sun exposure should be aware of this risk, though it is rare at standard therapeutic doses.\n\nSee our Ashwagandha page for another well-studied adaptogen approach to stress and mood.","deepText":"Evidence Review\n\nMeta-Analytic Evidence\n\nThe 2005 meta-analysis by Linde et al. synthesized 37 double-blind randomized controlled trials enrolling a combined several thousand patients [1]. Trials compared Hypericum monopreparations to placebo (26 trials) or standard antidepressants (14 trials). The pooled response rate versus placebo showed a relative risk of 1.28 to 1.87 depending on diagnostic criteria and outcome measures used.\n\nThe comparison to antidepressants showed equivalence (RR 1.00-1.02) with a consistently more favorable side-effect profile. Dropout rates due to adverse events were significantly lower for St. John's Wort across all comparative trials. The authors noted significant heterogeneity across studies, primarily attributed to differences in extract quality, standardization, and patient populations — reinforcing that extract quality is a meaningful variable.\n\nThe JAMA Severity Ceiling\n\nThe Hypericum Depression Trial Study Group (2002) enrolled 340 adults meeting DSM-IV criteria for major depression at the moderately severe level (Hamilton Depression Rating Scale score ≥20) [3]. Participants were randomized to H. perforatum 900-1500 mg/day, sertraline 50-100 mg/day, or placebo for 8 weeks.\n\nFull response rates: H. perforatum 14.3%, sertraline 24.8%, placebo 31.9%. Neither active treatment significantly outperformed placebo on the primary HAMD-17 outcome. On the secondary Clinical Global Impression scale, sertraline did outperform placebo, while H. perforatum did not.\n\nThis trial is frequently cited as evidence that St. John's Wort doesn't work — but a more accurate interpretation is that it highlights a severity ceiling: the herb performs better in mild-to-moderate depression, while severe depression (HAMD ≥20) may require more aggressive intervention. Notably, sertraline also failed the primary endpoint, illustrating how difficult severe depression is to treat in RCT conditions.\n\nMechanism: Hyperforin's Sodium Transporter Model\n\nSinger et al. (1999) established that hyperforin's mechanism differs fundamentally from classical reuptake inhibitors [2]. Rather than blocking transporter proteins directly, hyperforin activates sodium-conductive ion channels, raising intracellular sodium concentrations. This elevated sodium reduces the electrochemical gradient driving neurotransmitter uptake, effectively slowing reuptake of serotonin, dopamine, norepinephrine, GABA, and L-glutamate simultaneously.\n\nThis pan-reuptake inhibition — across five neurotransmitter systems — may partly explain why St. John's Wort has shown activity in conditions beyond depression, including anxiety, seasonal affective disorder, and premenstrual syndrome in smaller studies. It also means the receptor profile and downstream effects differ from SSRIs, which may be relevant for patients who respond poorly to serotonin-selective agents.\n\nExtracts with reduced hyperforin content (<1%) have shown consistently weaker antidepressant effects in clinical trials, confirming hyperforin as the principal bioactive constituent for mood effects.\n\nCYP3A4 Induction: Pharmacokinetic Evidence\n\nRoby et al. (2000) directly measured CYP3A4 activity in 13 healthy volunteers before and after 14 days of St. John's Wort (300 mg three times daily, 0.3% hypericin) [4]. CYP3A4 activity was quantified via urinary 6-beta-hydroxycortisol to cortisol ratio — a validated endogenous marker of CYP3A4 induction.\n\nAfter 14 days, the ratio increased significantly, confirming robust CYP3A4 induction at standard therapeutic doses. The authors flagged implications for drug-herb interactions across all CYP3A4-substrate medications.\n\nSubsequent pharmacokinetic studies confirmed that plasma concentrations of cyclosporine, indinavir, digoxin, warfarin, and oral contraceptive hormones are all reduced 30-50% or more by concurrent St. John's Wort use. These are clinically consequential reductions that have caused documented treatment failures and adverse events in transplant, HIV, and anticoagulation patients.\n\nEvidence Strength Assessment\n\n- Mild-to-moderate depression: Strong — supported by multiple RCTs and meta-analyses showing superiority to placebo and equivalence to SSRIs\n- Severe depression: Weak — limited by the JAMA 2002 findings; not recommended\n- Mechanism of action: Strong — hyperforin's sodium-channel model is well-characterized\n- Drug interactions (CYP3A4): Strong — direct pharmacokinetic evidence; clinical consequences documented\n- Anxiety, SAD, PMS: Preliminary — some positive signals in smaller trials, insufficient for firm conclusions\n\nSt. John's Wort is one of the best-evidenced herbal medicines available and deserves serious clinical consideration for mild to moderate depression — with equal seriousness given to its interaction profile before prescribing or recommending it alongside other medications.","deepTruncated":false,"references":[{"id":"1","title":"St John's wort for depression: meta-analysis of randomised controlled trials","authors":"Linde K, Berner M, Egger M, Mulrow C","year":2005,"journal":"British Journal of Psychiatry","pmid":"15684231","url":"https://pubmed.ncbi.nlm.nih.gov/15684231/"},{"id":"2","title":"Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+","authors":"Singer A, Wonnemann M, Müller WE","year":1999,"journal":"Journal of Pharmacology and Experimental Therapeutics","pmid":"10454515","url":"https://pubmed.ncbi.nlm.nih.gov/10454515/"},{"id":"3","title":"Effect of Hypericum perforatum (St John's Wort) in Major Depressive Disorder: A Randomized Controlled Trial","authors":"Davidson JR, Gadde KM, Fairbank JA, et al. (Hypericum Depression Trial Study Group)","year":2002,"journal":"JAMA","pmid":"11939866","url":"https://pubmed.ncbi.nlm.nih.gov/11939866/"},{"id":"4","title":"St John's Wort: effect on CYP3A4 activity","authors":"Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH","year":2000,"journal":"Clinical Pharmacology and Therapeutics","pmid":"10824623","url":"https://pubmed.ncbi.nlm.nih.gov/10824623/"}],"wordCount":1266,"source":{"path":"src/content/topics/st-johns-wort/depression-and-mood.md"},"citeAs":"“Does St John's wort work for depression?.” What's Healthy and Why. https://whatshealthyandwhy.com/st-johns-wort/depression-and-mood","notice":"General information backed by peer-reviewed research, not medical advice."}